Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider Amivantamab + Lazertinib combo for first line in EGFR mutated metastatic NSCLC, given the recent ESMO updates?
Related Questions
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How would you approach post-chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PD-L1 level?
Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?
How do you handle Grade 3-4 standard infusion reactions with Amivantamab?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?
